Amorfix Life Sciences in-licenses second novel technology to strengthen its ALS therapeutic program
The novel SOD1 targets were discovered by Dr. Avi Chakrabarrty and Mr. Rishi Rakhit at the University Health Network (UHN) and Dr. Neil Cashman, the company's Chief Scientific Officer, in his former academic laboratory at the University of Toronto. Dr. Cashman has assigned his portion of the technology rights to Amorfix. The company has licensed the remaining rights from UHN and has committed to invest a minimum of $260,000 on development of the technology at UHN.
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.